Loading...
Loading...
Generating destination analysis
Market Cap
$800M
P/E
N/A
Revenue Growth
+120.0%
Gross Margin
N/A
ROE
N/A
As a small-cap healthcare company trading on the NASDAQ, Nano-X Imaging has established itself, with direct, concentrated exposure to the biotech and genomics theme. Disruptive medical imaging company with novel cold-cathode X-ray technology at fraction of cost. With a $0.8B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +120% year-over-year.
Expert analysis and coverage for Nano-X Imaging
Or unlock everything now with Compass, $9/moPrice vs 200DMA
DMA Convergence
50 DMA
200 DMA
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.